A bit more than rapamycin but not a lot.
2 to 3x more than rapamycin. But that doesn’t compensate the big difference in mTOR inhibition.
1 Like
Some recent content published on Neurizon’s website (the pharma behind NUZ-001, which is the pill version of monepantel investigated for use in humans):
- NUZ-001 Shows Significant Blood-Brain Barrier Penetration
- NUZ-001 Shows Promise in a Model of Huntington’s Disease
- NUZ-001 Shows Positive Results in Human 3D Brain Model: “Results showed that NUZ-001 and NUZ-001 Sulfone exhibited strong safety characteristics in the ArtiBrainTM model (healthy human brain) and suggested short-term treatment: promotes health and viability of brain tissues, has neuroprotective properties against neurotoxic insult, may promote neuroplasticity by boosting neuronal branching”
- NUZ-001 Reduces Aggregation of Key ALS Disease Target
4 Likes
It’s interesting, I just don’t know enough to judge a drug in the preclinical or early clinical phase.